Medable Inc., a leading clinical development technology provider, has introduced Medable AI—a set of generative AI capabilities designed to help sponsors and clinical research organizations (CROs) accelerate the creation of digital and decentralized trials with full visibility and control over technology setup. Medable is the first to integrate generative AI into the study build process, aiming for a breakthrough one-day study startup. Medable AI, embedded in Medable Studio, automates time-consuming tasks, significantly reducing the time to First Patient In (FPI) and speeding up study startup. What traditionally took days to build outcomes assessments can now be completed in just 30 minutes.
Part of a broader AI initiative, Medable AI also offers features like automatic conversion of outcomes assessments into digital eCOAs in seconds and an easy-to-use, ChatGPT-like interface for creating and editing assessments. Medable aims to eliminate key barriers to digital trial adoption and plans to continue enhancing its AI offerings in 2025. The Medable AI-integrated Studio platform will be available in December 2024.
Medable has deployed its platform in over 300 decentralized trials across 70 countries, serving over one million participants and helping customers achieve significant results, including 90% eCOA adherence and cost reductions of up to 50%. Medable’s AI-driven approach is expected to further transform clinical trials, making them more accessible and efficient.
Click here to read the original news story.